GEN Exclusives

More »

GEN News Highlights

More »
Nov 30, 2011

Mayo Clinic, Karolinska Institutet Forge Long-Term Pact

  • U.S.-based Mayo Clinic and the Swedish medical university Karolinska Institutet are joining forces to advance healthcare research, innovation, and education. The two institutions will pursue joint investigations in regenerative medicine, individualized medicine, metabolism, neurosciences, and aging research.

    “We look forward to working with our colleagues in Sweden to advance healthcare for everyone,” says Robert Rizza, M.D., Kinney executive dean for research at Mayo Clinic. “Far beyond a simple academic agreement, this is a historic framework by which we will transform medicine and, for us at Mayo Clinic, extend our humanitarian mission to the world.”

    Harriet Wallberg-Henriksson, M.D., Ph.D., president of Karolinska Institutet, adds, “Mayo Clinic has succeeded in combining world-leading research with world-leading care, and we have much to learn from them organizationally and administratively, how to adapt our activities to first-class healthcare while conducting point-of-care research. They can learn from us, too. We have a long tradition of clinical research here, and it is more common for doctors to carry out research and have research training here than it is in the United States.”

    Karolinska Institutet’s research relationship with Mayo began over 15 years ago with joint studies in metabolism, diabetes, and nutrition, pioneered by Sree Nair, M.D., Ph.D., Mayo Clinic endocrinologist. That has now been expanded to other research areas, healthcare innovation, and education programs and exchanges.


Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

New Drugs for Ebola

Do you think that biopharma companies should not have to go through the normal drug approval process in order to get potential life-saving therapies to Ebola patients more quickly?